Compare EROK & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EROK | ALT |
|---|---|---|
| Founded | 2023 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.3M | 573.8M |
| IPO Year | 2026 | 2005 |
| Metric | EROK | ALT |
|---|---|---|
| Price | $21.76 | $2.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $28.83 | $17.11 |
| AVG Volume (30 Days) | 152.7K | ★ 3.0M |
| Earning Date | 11-19-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $154.84 | N/A |
| Revenue Next Year | $17.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $20.06 | $2.56 |
| 52 Week High | $27.42 | $6.44 |
| Indicator | EROK | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 29.36 |
| Support Level | $20.13 | $2.57 |
| Resistance Level | $22.53 | $3.35 |
| Average True Range (ATR) | 0.99 | 0.13 |
| MACD | -0.10 | -0.07 |
| Stochastic Oscillator | 38.19 | 4.40 |
EagleRock Land LLC is a surface-focused land management company, focused on providing access to land, resources, and infrastructure assets in the Permian Basin, including areas in Texas and New Mexico. Its assets support oil and natural gas development, as well as activities related to power generation, water infrastructure, and other industries. Through its land position and integrated infrastructure assets, the company generates revenue and royalties from completion and production-based activities, including surface damages, ROWs, easements, commercial water supply and produced water recycling, handling and disposal and other surface and subsurface related activities.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.